MACROUS jobless claims drop to 197,000, a level rare since the 1960sOct 8, 2026
EARNINGSStockStory rates Timken stock a hold with 5% EPS growthOct 8, 2026
DEALSHerbalife shares down 17.4% as analysts cite weak organic growthOct 8, 2026
$BTCBitcoin Holds Weekly Gains Amid $40 Trillion Debt ConcernsOct 8, 2026
REGULATORYAmphenol stock up 29.57% year to date as datacenter demand growsOct 8, 2026
$ETHBlackRock ETHB Draws Over $650 Million Since March LaunchOct 8, 2026
VTRSViatris to buy Pacira BioSciences for $1.65 billionOct 8, 2026
MACROFed hikes rates to 3.75%-4%, projects further tighteningOct 8, 2026
MACROUS jobless claims drop to 197,000, a level rare since the 1960sOct 8, 2026
EARNINGSStockStory rates Timken stock a hold with 5% EPS growthOct 8, 2026
DEALSHerbalife shares down 17.4% as analysts cite weak organic growthOct 8, 2026
$BTCBitcoin Holds Weekly Gains Amid $40 Trillion Debt ConcernsOct 8, 2026
REGULATORYAmphenol stock up 29.57% year to date as datacenter demand growsOct 8, 2026
$ETHBlackRock ETHB Draws Over $650 Million Since March LaunchOct 8, 2026
VTRSViatris to buy Pacira BioSciences for $1.65 billionOct 8, 2026
MACROFed hikes rates to 3.75%-4%, projects further tighteningOct 8, 2026

Herbalife shares down 17.4% as analysts cite weak organic growth

Herbalife stock fell to $12.45 over the past six months, a decline that erased 17.4% of shareholder capital while the S&P 500 climbed 15.2%. Analysts at StockStory are passing on the stock, citing sluggish organic revenue and declining…

By Kwame Asante·Oct 8, 2026·1 min read·deals

Herbalife stock fell to $12.45 over the past six months, a decline that erased 17.4% of shareholder capital while the S&P 500 climbed 15.2%. Analysts at StockStory are passing on the stock, citing sluggish organic revenue and declining profitability per share despite the lower entry price.

The firm emphasizes organic revenue growth as a key metric, which excludes one-time events like mergers and foreign currency fluctuations. Herbalife’s demand for products has remained stable over the last eight quarters but has lagged the broader sector. On average, the company posted year-on-year organic revenue growth of just 1.3% during that period.

Metric Value
Current Price $12.45
6-Month Stock Change -17.4%
S&P 500 Change (Same Period) +15.2%
Avg. Organic Revenue Growth (8 Quarters) 1.3%
3-Year EPS Decline -8.3% annually

Wall Street analysts forecast Herbalife’s revenue to rise by 2.1% over the next 12 months. This projection is close to the company’s 1% annualized growth rate over the past three years and suggests that newer products have not yet driven significant top-line performance. The analysts note that while accelerating growth typically boosts valuation multiples, this underwhelming outlook indicates a lack of near-term momentum.

Profitability concerns further complicate the investment case. Herbalife’s earnings per share (EPS) declined by 8.3% annually over the last three years, even as revenue grew by 1%. This divergence indicates the company became less profitable on a per-share basis while expanding its operations.

Despite these challenges, StockStory expresses limited confidence in the company's future performance. The firm suggests investors look toward other opportunities, specifically mentioning a top digital advertising platform riding the creator economy as a preferred alternative.

The source also highlights momentum stocks flagged by its AI platform, including Nvidia, which rose 1,460% between June 2020 and June 2025, and Exlservice, which gained 271% over the same period.

Share
© 2026 NewsMeter